Cargando…

Quality of life of men treated with brachytherapies for prostate cancer

BACKGROUND: Most studies of men undergoing treatment for prostate cancer examine physical symptoms as predictors of Quality of Life (QOL). However, symptoms vary by treatment modality in this population, and psychosocial variables, shown to be important to QOL, have rarely been examined. Litwin note...

Descripción completa

Detalles Bibliográficos
Autores principales: Lev, Elise L, Eller, Lucille Sanzero, Gejerman, Glen, Lane, Patricia, Owen, Steven V, White, Michele, Nganga, Njoki
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442132/
https://www.ncbi.nlm.nih.gov/pubmed/15198803
http://dx.doi.org/10.1186/1477-7525-2-28
_version_ 1782121551926132736
author Lev, Elise L
Eller, Lucille Sanzero
Gejerman, Glen
Lane, Patricia
Owen, Steven V
White, Michele
Nganga, Njoki
author_facet Lev, Elise L
Eller, Lucille Sanzero
Gejerman, Glen
Lane, Patricia
Owen, Steven V
White, Michele
Nganga, Njoki
author_sort Lev, Elise L
collection PubMed
description BACKGROUND: Most studies of men undergoing treatment for prostate cancer examine physical symptoms as predictors of Quality of Life (QOL). However, symptoms vary by treatment modality in this population, and psychosocial variables, shown to be important to QOL, have rarely been examined. Litwin noted a need for analysis of QOL data in men treated for prostate cancer with different modes of therapy, as studies focusing on specific treatments will increase the homogeneity of research findings. METHODS: This cross-sectional study explored physical and psychosocial predictors of QOL in men receiving one of two types of radiation treatment for prostate cancer: Intensity Modulated Radiation Therapy (IMRT) + High Dose Rate (HDR) Brachytherapy or IMRT + seed implantation. Subjects completed a biographic questionnaire; quality of life measures, which were the eight subscales of the Medical Outcome Study Short Form Health Survey (SF-36); measures of physical symptoms including the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) and the Prostate Symptom Self-Report (PSSR); and measures of psychological factors, the Ways of Coping Scale (WOC), Perceived Stress Scale, the Anxiety Subscale of the SCL-90, and Strategies Used by Patients to Promote Health (SUPPH). Eight regression models including both physical and psychosocial variables were used to predict quality of life. RESULTS: Sixty-three subjects with complete data on all variables were studied. Treatment effect sizes were medium to large in predicting each of the quality of life subscales of the SF-36. Psychosocial variables were related to physical function, role function, bodily pain, general health, social function, emotional role, and mental health. Physical symptoms were related to subjects' perceived general health and mental health. DISCUSSION: The number of significant relationships among psychosocial variables and indicators of QOL exceeded the number of relationships among symptoms and QOL suggesting that psychosocial variables associate strongly with prostate cancer patients' reports of quality of life. Findings of the study may provide patients and families with knowledge that contributes to their understanding of quality of life outcomes of IMRT+ HDR and IMRT + seed implantation and their ability to make more informed treatment choices.
format Text
id pubmed-442132
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-4421322004-07-03 Quality of life of men treated with brachytherapies for prostate cancer Lev, Elise L Eller, Lucille Sanzero Gejerman, Glen Lane, Patricia Owen, Steven V White, Michele Nganga, Njoki Health Qual Life Outcomes Research BACKGROUND: Most studies of men undergoing treatment for prostate cancer examine physical symptoms as predictors of Quality of Life (QOL). However, symptoms vary by treatment modality in this population, and psychosocial variables, shown to be important to QOL, have rarely been examined. Litwin noted a need for analysis of QOL data in men treated for prostate cancer with different modes of therapy, as studies focusing on specific treatments will increase the homogeneity of research findings. METHODS: This cross-sectional study explored physical and psychosocial predictors of QOL in men receiving one of two types of radiation treatment for prostate cancer: Intensity Modulated Radiation Therapy (IMRT) + High Dose Rate (HDR) Brachytherapy or IMRT + seed implantation. Subjects completed a biographic questionnaire; quality of life measures, which were the eight subscales of the Medical Outcome Study Short Form Health Survey (SF-36); measures of physical symptoms including the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) and the Prostate Symptom Self-Report (PSSR); and measures of psychological factors, the Ways of Coping Scale (WOC), Perceived Stress Scale, the Anxiety Subscale of the SCL-90, and Strategies Used by Patients to Promote Health (SUPPH). Eight regression models including both physical and psychosocial variables were used to predict quality of life. RESULTS: Sixty-three subjects with complete data on all variables were studied. Treatment effect sizes were medium to large in predicting each of the quality of life subscales of the SF-36. Psychosocial variables were related to physical function, role function, bodily pain, general health, social function, emotional role, and mental health. Physical symptoms were related to subjects' perceived general health and mental health. DISCUSSION: The number of significant relationships among psychosocial variables and indicators of QOL exceeded the number of relationships among symptoms and QOL suggesting that psychosocial variables associate strongly with prostate cancer patients' reports of quality of life. Findings of the study may provide patients and families with knowledge that contributes to their understanding of quality of life outcomes of IMRT+ HDR and IMRT + seed implantation and their ability to make more informed treatment choices. BioMed Central 2004-06-15 /pmc/articles/PMC442132/ /pubmed/15198803 http://dx.doi.org/10.1186/1477-7525-2-28 Text en Copyright © 2004 Lev et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research
Lev, Elise L
Eller, Lucille Sanzero
Gejerman, Glen
Lane, Patricia
Owen, Steven V
White, Michele
Nganga, Njoki
Quality of life of men treated with brachytherapies for prostate cancer
title Quality of life of men treated with brachytherapies for prostate cancer
title_full Quality of life of men treated with brachytherapies for prostate cancer
title_fullStr Quality of life of men treated with brachytherapies for prostate cancer
title_full_unstemmed Quality of life of men treated with brachytherapies for prostate cancer
title_short Quality of life of men treated with brachytherapies for prostate cancer
title_sort quality of life of men treated with brachytherapies for prostate cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442132/
https://www.ncbi.nlm.nih.gov/pubmed/15198803
http://dx.doi.org/10.1186/1477-7525-2-28
work_keys_str_mv AT levelisel qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer
AT ellerlucillesanzero qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer
AT gejermanglen qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer
AT lanepatricia qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer
AT owenstevenv qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer
AT whitemichele qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer
AT nganganjoki qualityoflifeofmentreatedwithbrachytherapiesforprostatecancer